Skip to content
Toggle navigation
Sign Up
Contact
Twitter
LinkedIn
Search
Search
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University School of Law
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
Funding Themes
2024 Solicitation
Application Process
Entering Portfolio
Apply Here
Omnibus Outcomes
Resources
CARB-X Connect
Presentations
Videos
Publications
Education
PD Resources
Fact Sheets
AMR Test Directory
Research Compliance
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Product Developer News
Events
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University School of Law
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
Funding Themes
2024 Solicitation
Application Process
Entering Portfolio
Applicant Questions (2019)
Resources
Presentations
Videos
Publications
Education
PD Resources
Fact Sheets
AMR Test Directory
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Product Developer News
Events
Contact
Legal
News
FDA grants HelixBind breakthrough device designation for RaPID sepsis test
FDA grants HelixBind breakthrough device designation for RaPID sepsis test
We use cookies to ensure that we give you the best experience on our website. By clicking “Ok”, you consent to the use of all cookies.
Ok
Toggle navigation
Toggle navigation